Healthcare Services

A key trend shaping the Arthralgia Market involves the RMAT Designation Granted For Gene Therapy In Osteoarthritis Treatment

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Arthralgia Market Projected To Become By 2030 Based On Its 2026 Valuation?

The arthralgia market has experienced significant growth in recent years. It is anticipated to expand from $5.62 billion in 2025 to $6.09 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by the increasing occurrence of joint-related conditions, a growing elderly population, heightened understanding of musculoskeletal well-being, the availability of more pharmaceutical options for pain management, and the growth of orthopedic care provided in outpatient settings.

The arthralgia market is projected to experience substantial expansion over the upcoming years. By 2030, its valuation is anticipated to reach $8.26 billion, demonstrating a compound annual growth rate (CAGR) of 7.9%. This anticipated growth during the forecast period stems from several factors, including the escalating demand for tailored treatment plans, the expanding embrace of biologic and targeted therapies, the wider availability of at-home pain management options, an intensifying focus on sustained symptom management, and increased investments in research dedicated to joint health. Key trends defining this period encompass the growing acceptance of individualized pain management strategies, a rise in the application of combined treatment methods, an amplified emphasis on promptly diagnosing joint conditions, the proliferation of non-invasive options for pain relief, and improved patient-centric care models.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21104&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Arthralgia Market?

A growing number of rheumatoid arthritis instances is projected to stimulate the expansion of the arthralgia market in the future. Rheumatoid arthritis is a persistent autoimmune condition that predominantly impacts joints, causing inflammation, discomfort, and potential structural harm to them. The escalating prevalence of rheumatoid arthritis cases can be attributed to factors like an aging demographic, inherited susceptibility, shifts in lifestyle, and environmental elements including smoking and air contamination. Rheumatoid arthritis (RA) contributes to arthralgia by initiating long-term joint inflammation, which results in pain, rigidity, and gradual deterioration. As an illustration, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit organization, indicates that by 2040, arthritis cases in Australia are anticipated to climb to 5.39 million from 4.11 million in 2025, with osteoarthritis projected to grow to 3.11 million from 2.35 million, and rheumatoid arthritis expected to reach 748,721. Consequently, the expanding incidence of rheumatoid arthritis is fueling the expansion of the arthralgia market.

What Segment Groups Are Identified Within The Arthralgia Market?

The arthralgia market covered in this report is segmented –

1) By Cause: Osteoarthritis, Rheumatoid Arthritis, Gout, Psoriatic Arthritis, Lupus, Injuries, Infections, Other Causes

2) By Treatment Type: Medications, Therapies, Surgical Interventions, Lifestyle And Home Remedies

3) By Route Of Administration: Oral, Injectable, Topical, Transdermal

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospital, Clinics, Homecare Settings, Rehabilitation Centers

Subsegments:

1) By Osteoarthritis: Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Spine Osteoarthritis, Shoulder Osteoarthritis

2) By Rheumatoid Arthritis: Seropositive Rheumatoid Arthritis, Seronegative Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Early-Onset Rheumatoid Arthritis

3) By Gout: Primary Gout, Secondary Gout, Gouty Arthritis

4) By Psoriatic Arthritis: Symmetric Psoriatic Arthritis, Asymmetric Psoriatic Arthritis, Psoriatic Spondylitis, Distal Interphalangeal Predominant Psoriatic Arthritis

5) By Lupus: Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus, Drug-induced Lupus, Neonatal Lupus

6) By Injuries: Sports-related Injuries, Trauma and Fractures, Sprains and Strains, Tendon or Ligament Damage

7) By Infections: Septic Arthritis, Viral Arthritis, Bacterial Infections, Fungal Infections

8) By Other Causes: Fibromyalgia, Overuse Injuries, Sarcoidosis, Ankylosing Spondylitis, Crystal-induced Arthritis

Which Trends Are Impacting The Growth Of The Arthralgia Market?

Leading companies in the arthralgia market are prioritizing the creation of novel therapies, including RMAT-designated gene therapy, aiming to offer patients advanced solutions for sustained pain relief and enhanced joint function. An RMAT-designated gene therapy is a form of treatment granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA, a status that accelerates the development and evaluation of groundbreaking gene therapies for severe or life-threatening ailments. For example, in March 2024, the U.S. Food and Drug Administration (FDA) awarded Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), a product from Pacira BioSciences Inc., a US-based pharmaceutical firm. This candidate is an inventive intra-articular gene therapy that employs a helper-dependent adenovirus (HDAd) for addressing knee osteoarthritis. The therapy’s mechanism involves generating interleukin-1 receptor antagonists (IL-1Ra). Pacira expressed its satisfaction in securing the FDA’s inaugural RMAT designation for an osteoarthritis-focused gene therapy and highlighted the encouraging early clinical outcomes, indicating that PCRX-201 could potentially be a disease-modifying intervention.

Which Companies Hold Significant Positions In The Arthralgia Market?

Major companies operating in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation

Read the full arthralgia market report here:

https://www.thebusinessresearchcompany.com/report/arthralgia-global-market-report

Which Regions Are Projected To Dominate The Arthralgia Market In The Coming Years?

North America was the largest region in the arthralgia market in 2025. The regions covered in the arthralgia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Arthralgia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21104&type=smp

Browse Through More Reports Similar to the Global Arthralgia Market 2026, By The Business Research Company

Anthracite Global Market Report

https://www.thebusinessresearchcompany.com/report/anthracite-global-market-report

Artichokes Global Market Report

https://www.thebusinessresearchcompany.com/report/artichokes-global-market-report

Lenalidomide Global Market Report

https://www.thebusinessresearchcompany.com/report/lenalidomide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795